159 related articles for article (PubMed ID: 16614734)
1. ATC0175: an orally active melanin-concentrating hormone receptor 1 antagonist for the potential treatment of depression and anxiety.
Chaki S; Yamaguchi J; Yamada H; Thomsen W; Tran TA; Semple G; Sekiguchi Y
CNS Drug Rev; 2005; 11(4):341-52. PubMed ID: 16614734
[TBL] [Abstract][Full Text] [Related]
2. Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists.
Chaki S; Funakoshi T; Hirota-Okuno S; Nishiguchi M; Shimazaki T; Iijima M; Grottick AJ; Kanuma K; Omodera K; Sekiguchi Y; Okuyama S; Tran TA; Semple G; Thomsen W
J Pharmacol Exp Ther; 2005 May; 313(2):831-9. PubMed ID: 15677346
[TBL] [Abstract][Full Text] [Related]
3. Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1.
Kanuma K; Omodera K; Nishiguchi M; Funakoshi T; Chaki S; Semple G; Tran TA; Kramer B; Hsu D; Casper M; Thomsen B; Sekiguchi Y
Bioorg Med Chem Lett; 2005 Sep; 15(17):3853-6. PubMed ID: 16002290
[TBL] [Abstract][Full Text] [Related]
4. Prodepressive effect induced by microinjections of MCH into the dorsal raphe: time course, dose dependence, effects on anxiety-related behaviors, and reversion by nortriptyline.
Urbanavicius J; Lagos P; Torterolo P; Scorza C
Behav Pharmacol; 2014 Aug; 25(4):316-24. PubMed ID: 25006977
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant/anxiolytic potential and adverse effect liabilities of melanin-concentrating hormone receptor 1 antagonists in animal models.
Chaki S; Shimazaki T; Nishiguchi M; Funakoshi T; Iijima M; Ito A; Kanuma K; Sekiguchi Y
Pharmacol Biochem Behav; 2015 Aug; 135():154-68. PubMed ID: 26044968
[TBL] [Abstract][Full Text] [Related]
6. Anxiolytic effects of the MCH1R antagonist TPI 1361-17.
Lee C; Parks GS; Civelli O
J Mol Neurosci; 2011 Feb; 43(2):132-7. PubMed ID: 20635163
[TBL] [Abstract][Full Text] [Related]
7. Recent updates on the melanin-concentrating hormone (MCH) and its receptor system: lessons from MCH1R antagonists.
Chung S; Parks GS; Lee C; Civelli O
J Mol Neurosci; 2011 Jan; 43(1):115-21. PubMed ID: 20582487
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.
Iijima M; Yoshimizu T; Shimazaki T; Tokugawa K; Fukumoto K; Kurosu S; Kuwada T; Sekiguchi Y; Chaki S
Br J Pharmacol; 2014 Jul; 171(14):3511-25. PubMed ID: 24654684
[TBL] [Abstract][Full Text] [Related]
9. Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.
Semple G; Tran TA; Kramer B; Hsu D; Han S; Choi J; Vallar P; Casper MD; Zou N; Hauser EK; Thomsen W; Whelan K; Sengupta D; Morgan M; Sekiguchi Y; Kanuma K; Chaki S; Grottick AJ
Bioorg Med Chem Lett; 2009 Nov; 19(21):6166-71. PubMed ID: 19773162
[TBL] [Abstract][Full Text] [Related]
10. Melanin-concentrating hormone MCH1 receptor antagonists: a potential new approach to the treatment of depression and anxiety disorders.
Shimazaki T; Yoshimizu T; Chaki S
CNS Drugs; 2006; 20(10):801-11. PubMed ID: 16999451
[TBL] [Abstract][Full Text] [Related]
11. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders.
Griebel G; Simiand J; Steinberg R; Jung M; Gully D; Roger P; Geslin M; Scatton B; Maffrand JP; Soubrié P
J Pharmacol Exp Ther; 2002 Apr; 301(1):333-45. PubMed ID: 11907191
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
Dawson LA; Hughes ZA; Starr KR; Storey JD; Bettelini L; Bacchi F; Arban R; Poffe A; Melotto S; Hagan JJ; Price GW
Neuropharmacology; 2006 Jun; 50(8):975-83. PubMed ID: 16581092
[TBL] [Abstract][Full Text] [Related]
13. Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450.
Chaki S; Nakazato A; Kennis L; Nakamura M; Mackie C; Sugiura M; Vinken P; Ashton D; Langlois X; Steckler T
Eur J Pharmacol; 2004 Feb; 485(1-3):145-58. PubMed ID: 14757135
[TBL] [Abstract][Full Text] [Related]
14. Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral, and corticolimbic neurochemical stress responses in mice.
Smith DG; Davis RJ; Rorick-Kehn L; Morin M; Witkin JM; McKinzie DL; Nomikos GG; Gehlert DR
Neuropsychopharmacology; 2006 Jun; 31(6):1135-45. PubMed ID: 16205780
[TBL] [Abstract][Full Text] [Related]
15. Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression.
Wesołowska A; Nikiforuk A; Stachowicz K; Tatarczyńska E
Neuropharmacology; 2006 Sep; 51(3):578-86. PubMed ID: 16828124
[TBL] [Abstract][Full Text] [Related]
16. Effects of histamine H3 receptor ligands in experimental models of anxiety and depression.
Pérez-García C; Morales L; Cano MV; Sancho I; Alguacil LF
Psychopharmacology (Berl); 1999 Feb; 142(2):215-20. PubMed ID: 10102775
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant-like and anxiolytic-like effects of YL-IPA08, a potent ligand for the translocator protein (18 kDa).
Zhang LM; Zhao N; Guo WZ; Jin ZL; Qiu ZK; Chen HX; Xue R; Zhang YZ; Yang RF; Li YF
Neuropharmacology; 2014 Jun; 81():116-25. PubMed ID: 24067925
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.
Hodgson RA; Mullins D; Lu SX; Guzzi M; Zhang X; Bleickardt CJ; Scott JD; Miller MW; Stamford AW; Parker EM; Varty GB
Eur J Pharmacol; 2014 May; 730():157-63. PubMed ID: 24602808
[TBL] [Abstract][Full Text] [Related]
19. Investigation of antidepressant-like and anxiolytic-like actions and cognitive and motor side effects of four N-methyl-D-aspartate receptor antagonists in mice.
Refsgaard LK; Pickering DS; Andreasen JT
Behav Pharmacol; 2017 Feb; 28(1):37-47. PubMed ID: 27740963
[TBL] [Abstract][Full Text] [Related]
20. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
Griebel G; Simiand J; Serradeil-Le Gal C; Wagnon J; Pascal M; Scatton B; Maffrand JP; Soubrie P
Proc Natl Acad Sci U S A; 2002 Apr; 99(9):6370-5. PubMed ID: 11959912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
